CLAIMS

1. Use of:

(i) Elafibranor (ELA) or a pharmaceutically acceptable salt thereof; and

(ii) a FXR agonist selected from the group consisting of obeticholic acid (OCA), a pharmaceutically acceptable salt of OCA, INT-767 and a pharmaceutically acceptable salt of INT-767,

in the preparation of a medicament for combination therapy for the treatment of an immune, inflammatory, metabolic, fibrotic or cholestatic disease, wherein the disease is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).

2. The use according to claim 1, wherein the FXR agonist is Obeticholic acid (OCA) or a pharmaceutically acceptable salt thereof; and wherein:

- ELA is for administration at a dose comprised between 5 and 80 mg/day and OCA is for administration at a dose comprised between 7 and 17 mg/day;
- ELA is for administration at a dose comprised between 40 and 60 mg/day and OCA is for administration at a dose comprised between 5 and 12.5 mg/day;
- ELA is for administration at a dose comprised between 32 and 48 mg/day and OCA is for administration at a dose comprised between 4 and 10 mg/day;
- ELA is for administration at a dose comprised between 27 and 40 mg/day and OCA is for administration at a dose comprised between 3 and 8 mg/day;
- ELA is for administration at a dose comprised between 16 and 24 mg/day and OCA is for administration at a dose comprised between 2 and 5 mg/day; or
- ELA is for administration at a dose comprised between 8 and 12 mg/day and OCA is for administration at a dose comprised between 1 and 2.5 mg/day.

3. Use according to claim 1 or 2, wherein (i) and (ii) are for separate, sequential or simultaneous administration.